TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05367895

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use.

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use.

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use.
Study: NCT03127267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (6.0)
Description: Masitinib (titration to 6.0 mg/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 50 mg tablet, treatment per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 50 mg tablet, treatment per os
Study: NCT05799131

Intervention type: DEVICE
Intervention: QBX (5F/6F) Peripheral Balloon Expandable Stent System
Description: The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths.
Study: NCT05900037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATT-Patch
Description: GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL® Original
Description: SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
Study: NCT05888142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in clinic pain VR reduction exercises
Description: During the in clinic training phase, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality. But this group will not take a VR system home until after completing the in clinic training phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In clinic VRpain reduction exercises + VR homeworks
Description: During the training phase, participants will use commercially available VR during in clinic physical therapy exercises, and during the training phase, they will also receive a VR system they take home and will begin VR homeworks during the traininng phase, to help reduce their pain and improve functionality.
Study: NCT05928910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmileyScope VR
Description: The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
Study: NCT03127267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Riluzole 50 mg tablet, treatment per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment per os
Study: NCT05396053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy exercises
Description: Three times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercises
Description: Three times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercises
Description: Three times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Three times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Three times a week for 12 weeks.
Study: NCT05211427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
Study: NCT05590975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intervention
Description: PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intervention
Description: PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
Study: NCT04345562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin preparation patterns with ChloraPrep 2 x 26 mL single
Description: 2 different patterns of skin preparation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin preparation patterns with ChloraPrep 2 x 26 mL single
Description: 2 different patterns of skin preparation
Study: NCT04693559

Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps

Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps

Intervention type: PROCEDURE
Group type: OTHER
Intervention: harvesting of the autogenous bone graft
Description: osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nanocrystalline Hydroxyapatite
Description: Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
Study: NCT06123078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: Culturally adapted Self help guide and modules total eight 80 hour session per week
Study: NCT05928403

Intervention type: OTHER
Intervention: total knee prosthesis
Description: Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis

Intervention type: OTHER
Intervention: total knee prosthesis
Description: Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis

Intervention type: OTHER
Intervention: total knee prosthesis
Description: Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
Study: NCT05161923

Intervention type: PROCEDURE
Intervention: Per oral endoscopy myotomy
Description: The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
Study: NCT04758065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial pressure waves Therapy
Description: Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Experimental Group: Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise and Manual Therapy
Description: Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy.
Study: NCT05991102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic field treatment
Description: Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
Study: NCT05431543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: LNZ101-combination ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine ophthalmic solution
Description: LNZ100- aceclidine ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle proprietary ophthalmic solution
Description: Proprietary Vehicle ophthalmic solution
Study: NCT03127267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (4.5)
Description: Masitinib (titration to 4.5 mg/kg/day)
Study: NCT04758065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise and Manual Therapy
Description: Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy.
Study: NCT05306587

Intervention type: DRUG
Intervention: Darzalex
Description: Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
Study: NCT04303559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate Injectable Product
Description: This is a factor VIII-Fc fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab Injection [Hemlibra]
Description: This is a bispecific monoclonal antibody FVIII mimic.
Study: NCT05393635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion.
Study: NCT05809609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (placebo)
Description: Placebo injection (0.9% sodium chloride)
Study: NCT05276817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic Diode
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic Diode
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
Study: NCT06263478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA034176
Description: IV infusion
Study: NCT05039957

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: joint preparation
Description: fixation of fracture with joint preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without joint preparation
Description: fixation of fracture without joint preparation
Study: NCT04911569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Cryoneurolysis
Study: NCT06048159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tACS
Description: High definition tACS will be applied during speech therapy.
Study: NCT06207045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb elevation
Description: limb elevation more than 45 degrees
Study: NCT06048159

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tACS
Description: Sham high definition tACS will be applied during speech therapy.
Study: NCT06576076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for cannabis abstinence
Description: Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
Study: NCT05441267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Oral Tablet
Description: Oral semaglutide 14mg daily (option to reduce to 7mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral semaglutide
Study: NCT06087224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleneonatology
Description: Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
Study: NCT06669117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERT-002
Description: Route of Administration: Intravenous
Study: NCT06304207

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Onsite Maintenance Exercise Training
Description: Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telehealth Maintenance Exercise
Description: Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
Study: NCT06440005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGX101
Description: Antibody Drug Conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGX101
Description: Antibody Drug Conjugate
Study: NCT06627335

Intervention type: DRUG
Intervention: Ruxolitinib Cream
Description: Ruxolitinib Cream

Intervention type: DRUG
Intervention: TCS
Description: Topical corticosteroid